Dr. Ali Fattom Joins NanoBio to Lead the Company’s Vaccine Research Efforts

ANN ARBOR, Mich.--(BUSINESS WIRE)-- NanoBio Corporation today announced that Ali I. Fattom, Ph.D., has joined the company as Senior Vice President of Vaccine Research and Development. Dr. Fattom was previously Vice President of Research and Early Development at Nabi Biopharmaceuticals. In his new position, Dr. Fattom will draw upon his more than two decades of experience in vaccine research to lead NanoBio’s nanoemulsion-based intranasal and intramuscular vaccine programs.

“NanoBio’s novel adjuvant and vaccine platform has the potential to revolutionize the vaccination for many diseases worldwide,” said Dr. Fattom. “Given NanoBio has just completed a successful first-in-man Phase 1 study of a nanoemulsion-adjuvanted influenza vaccine, it is truly an exciting time to join the company. I look forward to leading the company’s future research efforts in seasonal and pandemic influenza, as well as our other vaccine targets including respiratory syncytial virus, therapeutic hepatitis B and urinary tract infections.”

“Dr. Fattom has the extensive experience and commitment to excellence required to effectively set the pace for NanoBio’s vaccine program going forward,” said James Baker Jr., MD, founder and CEO of NanoBio. “He brings the knowledge and hands-on experience to lead the R&D efforts for vaccine candidates we plan to develop on our own. In addition, Dr. Fattom brings a track record of successfully collaborating with other pharmaceutical companies, which will be critical as we consider opportunities to partner our adjuvant for use in effectively vaccinating against other respiratory, sexually transmitted and even addictive diseases.”

Dr. Fattom initiated his career as a vaccinologist at The National Institutes of Health where he helped develop several vaccines including a Pneumococcus conjugate vaccine and a S. aureus vaccine. More recently as Vice President of Research for Nabi Biopharmaceuticals, he played a key role in the development of a conjugate vaccine against Staphylococci and a vaccine against nicotine addiction. He earned a B.S. from The Hebrew University of Jerusalem, a M.S. in Microbiology from Tel-Aviv University, and a Ph.D. in Microbial Ecology from the Hebrew University of Jerusalem. Dr. Fattom is author of over 50 peer reviewed publications, and holds more than 10 patents.

About NanoBio’s Vaccine Program

The company’s nanoemulsion-based vaccine adjuvant platform offers numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles. NanoBio’s vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. In 2010, the company successfully completed its first-in-man study of a nanoemulsion-adjuvanted intranasal vaccine, demonstrating safety and eliciting both mucosal and systemic immunity against seasonal influenza.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.



CONTACT:

NanoBio
John Coffey, 734-302-9107
Vice President, Business Development
[email protected]
or
Schwartz Communications
Stacey Holifield or Benjamin Navon, 781-684-0770
[email protected]

KEYWORDS:   United States  North America  Michigan

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  Other Health  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.